NCT01975142View on ClinicalTrials.gov

Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.

PHASE2CompletedINTERVENTIONAL
Enrollment

155

Participants

Timeline

Start Date

November 7, 2013

Primary Completion Date

February 13, 2018

Study Completion Date

January 21, 2019

Conditions
Metastatic Breast Cancer, HER2 Negative Primary Tumor
Interventions
DRUG

Trastuzumab - Emtansine

Trial Locations (10)

34298

Centre Val d'Aurelle - P. Lamarque, Montpellier

54519

Centre Catherine de Sienne, Vandœuvre-lès-Nancy

Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy

59020

Centre Oscar Lambret, Lille

72000

Clinique Victor Hugo, Le Mans

75005

Institut Curie, Paris

75475

Chu Saint-Louis, Paris

87042

Chu de Limoges, Limoges

92309

Institut de Cancérologie HARTMANN, Levallois-Perret

SAINT-CLOUD

Institut Curie - Hôpital René HUGENIN, Saint-Cloud

All Listed Sponsors
lead

Institut Curie

OTHER

NCT01975142 - Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment. | Biotech Hunter | Biotech Hunter